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Nanotechnology having developed exponentially, the aim has been on therapeutic undertaking, particularly for
cancerous disease chemotherapy. Nanostructured lipid carriers have attracted expanding scientific and commercial
vigilance in the last couple of years as alternate carriers for the pharmaceutical consignment, particularly anticancer
pharmaceuticals. Shortcomings often came across with anticancer mixtures, such as poor solubility, normal tissue
toxicity, poor specificity and steadiness, as well as the high incidence rate of pharmaceutical resistance and the
rapid degradation, need of large-scale output procedures, a fast release of the pharmaceutical from its carrier
scheme, steadiness troubles, the residues of the organic solvents utilized in the output method and the toxicity
from the polymer with esteem to the carrier scheme are anticipated to be overcome through use of the
Nanostructured Lipid Carrier. In this review the benefits, types, drug release modulations, steadiness and output
techniques of NLCs are discussed. In supplement, the function of NLC in cancer chemotherapy is presented and
hotspots in research are emphasized. It is foreseen that, in the beside future, nanostructured lipid carriers will be
further advanced to consign cytotoxic anticancer compounds in a more efficient, exact and protected manner.
Keywords: Nanostructured lipid carriers, cancer chemotherapy, controlled drug release, increased drug load,
stability, tissue targetIntroduction
In the pharmaceutical breakthrough today, the new
technologies lead to find numerous new mighty com-
pounds. To double-check progress in drug therapy the
development of new drugs solely is not sufficient. Poor
water solubility and insufficient bioavailability of the new
drug substances are very widespread issues encountered.
Thus, there is an expanding need to develop a pharma-
ceutical carrier scheme that overcomes these matters.
This carrier scheme should be free of toxicity, have an
adequate pharmaceutical loading capability and the
possibility of pharmaceutical targeting and controlled
release characteristics. The system should provide chem-
ical and personal steadiness for the incorporated
pharmaceutical. The feasibility of the production tech-
nique and as well the affordability should also be access-
ible [1-3].
Colloidal systems enquired have their own disadvan-
tages. Shortcomings often encountered with the colloidal* Correspondence: smk1976@gmail.com
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use, distribution, and reproduction in any medschemes such as liposomes, micro and nanoemulsions,
nanocapsules, nanosponges and polymeric nanoparticles
are the rapid degradation by the pH of the stomach or
by the intestinal enzymes and the bile salts if taken or-
ally, restricted physical and chemical steadiness through-
out storage [4-6], need of large-scale output methods, a
fast release of the drug from its carrier system, stability
difficulties, the residues of the organic solvents used in
the output method, the toxicity from the polymer [7,8]
and numerous to say. All of these points make these col-
loidal carriers not optimal as a pharmaceutical carrier
system.
SLN have been presented as an alternate carrier
scheme to emulsions, liposomes and polymeric nanopar-
ticles. SLN are formulated from solid lipids only. There-
fore, after groundwork at smallest a part of the particles
crystallizes in a higher energy modification (α or β`).
Throughout storage, these modifications can transform
to the low power, more organised β modification. Due to
this modification high degree of alignment, the number
of imperfections in the crystal lattice is small; this directs
to drug expulsion [9].ensee BioMed Central Ltd. This is an Open Access article distributed under the
icense (http://creativecommons.org/licenses/by/2.0), which permits unrestricted
ium, provided the original work is properly cited.
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backs affiliated with SLN. They are advised to be the
second lifetime of lipid nanoparticles. Contrasted to
SLN, NLC show a higher loading capability for hard-
working compounds by conceiving a less organized solid
lipid matrix, i.e. by blending a fluid lipid with the solid
lipid, a higher element drug stacking can be achieved.
Thus, the NLC have an expanded drug stacking capacity
in evaluation to SLN and the likelihood of drug expul-
sion during storage is less [2,10-12]. NLC have also a
lower water content of the element suspension and a
less inclination of unpredictable gelation [12-14].
NLC disclosed some benefits contrasted to the other
colloidal carrier schemes. They supply a controlled
pharmaceutical issue and an increase in chemical stabil-
ity of the incorporated drugs. Furthermore, they are pro-
tected carriers which can be produced effortlessly on
large scale [2,12,15-17].
Nanostructured lipid carrier’s classification
It is well renowned from the study of suppositories that
highly organized crystalline lipid matrices will lead to
pharmaceutical expulsion. Lipid nanoparticles and
microparticles made from blends of solid lipids can ex-
perience this, especially when nanoparticles are arranged
from highly purified lipids, for example, tristearin [18].
The formation of highly ordered βi or β modifications,
particularly during storage, departs little space for
pharmaceutical molecules, and the expulsion of pharma-
ceuticals leads to drug crystals in suspensions and solid
dosage forms. To avoid this difficulty, the particles
should have a controlled nanostructure that boasts
enough space to accommodate the pharmaceutical. Four
distinct approaches were taken for an optimized nanos-
tructure of NLCs. In kind I, solid lipids and fluid lipids
(oils) are blended. The difference in the organizations of
the lipids and exceptional requirements in the
crystallization process lead to a highly disordered,Figure 1 SLN with high crystallinity and Different types of NLC. I – Hig
amorphous NLC.imperfect lipid matrix structure proposing space for
drug substances and amorphous clusters of pharmaceu-
ticals (Figure 1, I).
In general, drug solubility is higher in fluid lipids than
in solid lipids. Founded on this, particles were produced
with a high content of liquid lipids (oils). Throughout
the production method, the liquid lipid particles (nanoe-
mulsions) are chilled from the molten state to room
warmth to crystallize and pattern solid particles. At high
oil concentrations a miscibility gap of the two lipids
(solid lipid plus oil) happens throughout the chilling
phase, leading to stage separation, that means precipita-
tion of minute oily nanocompartments (Figure 1, II). In
this multiple oil/fat/water, kind II drug can be accom-
modated in the solid, but at increased solubility in the
oily components of the lipid matrix.
In type III, lipids are blended in a way that stops them
from crystallizing. The lipid matrix is solid, but in an
amorphous state (Figure 1, III) [19]. The nonattendance
of crystallization avoids pharmaceutical expulsion by
crystallization. Lipid particles are preferentially matched
to incorporate lipophilic pharmaceuticals; hydrophilic
drugs can only be incorporated at a low percentage
(however, this is still sufficient for highly powerful pep-
tides and proteins). In a further variation of the lipid
matrix, water-soluble pharmaceuticals were conjugated
with a lipid, thus forming a water-insoluble lipidic conju-
gate. The lipid conjugate dust was dissolved and pro-
cessed in the same way as the other types to yield a lipid
drug conjugate (LDC) nanoparticle [20] counting on the
conjugate, this lipidic conjugate has a pharmaceutical
stacking of up to 30–50% for water-soluble pharmaceuti-
cals. Conjugation is presented by salt formation or cova-
lent linkage.
Modulation of Pharmaceutical Release
Pharmaceutical issue from lipid particles happens by dif-
fusion and simultaneously by lipid element degradationhly imperfect matrix, II – Multiple O/F/W type, III – non-crystalline
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a controlled very quick release going after diffusion and
degradation. Perfectly this issue should be triggered by
an impulse when the particles are administered. NLCs
accommodate the pharmaceutical because of their highly
unordered lipid organizations. By applying the initiate
impulse to the matrix to alter in a more ordered struc-
ture, such a desired blew pharmaceutical release can be
started. NLCs of certain organizations can be triggered
this way; for demonstration, when applying the particles
to the skin incorporated in a cream. Boost in warmth
and water evaporation leads to a boost in pharmaceutical
issue rate (Figure 2). Founded on these cyclosporine-lipid
particles are under development to heal psoriasis [21,22].
The cream itself is saturated with cyclosporine, as well as
a cyclosporine-loaded NLC contained in the cream. After
application to the skin, accelerated issue from the lipid
particles should lead to a supersaturated scheme (similar
to micro emulsions, but without high surfactant engross-
ment) premier to an improved penetration of cyclosporine
into the skin.
Long-Term Stability
During long-term storage of dispersions, element aggre-
gation can happen. Aggregation and case formation were
described for SLNs [23]. Lone particles diffuse in the dis-
persion medium; collision of particles can lead to periki-
netic flocculation (Figure 3a). In the highly intensified
NLC dispersions the particles pattern a ‘pearl-like net-
work’, thus the particles are in a repaired place and will
not undergo collision and perikinetic flocculation. After
management of the particles and dilution with fluids
(gastrointestinal fluids, for example), the mesh is decimated
issuing single, non-aggregated particles (Figure 3b). Lipid
particle dispersions were produced at identical surfactant
concentration, but with reduced lipid content (be reduced
30%, outside patent coverage) and with 35% lipid. The lowFigure 2 Triggered pharmaceutical releases from NLC by starting the
organized stable modifications.element dispersion aggregated during storage time, the gel-
like NLC dispersion remained stable throughout storage
and, after dilution, and single particles were obtained dis-
playing no size boost [24] (Figure 4).
Output of NLCs
NLCs can be made by various traditional dispersion
methods. The favored output method is solvent diffusion
method which was even said to be the most befitting
procedure for the preparation of the nanoparticles [25].
Few other methods are Homogenization technique,
double emulsion, supercritical fluid technology etc. High
pressure homogenization technique is highlighted here.
First the lipid phase is melted. Then the drug is dis-
solved in the molten lipid preparing a drug containing
lipid melt. This melt is then dispersed in an aqueous sur-
factant solution heated at the same temperature, using a
high speed stirring. The obtained pre-emulsion is then
homogenized. The hot o/w emulsion obtained is solidi-
fied by cooling down to room temperature. The solidifi-
cation of the Nano emulsions produced Nanostructured
lipid carriers. The highly concentrated NLC dispersions
are highly viscous, gel-like or pasty. These systems have
no flowability. To make an 80% NLC dispersion, a multi-
step production method is directed. First, a 50% SLN
dispersion is made by high-pressure homogenization.
One hundred grams of such dispersion comprises 50 g
of lipid and 50 g of water. In the next step, 10 g of lipid
is supplemented, which is dispersed by high-speed stir-
ring in the remaining 50 g of water. This outcome in
110 g of dispersion encompassing 60 g of lipid (55%)
and a fresh 50 g of water. In the next step, another 10 g
of lipid is dispersed in this 50 g of water stage and so on
until a lipid content of 80% is come to. Large-scale pro-
duction of NLC is easily possible. High-pressure homo-
genizers are accessible to method one ton and more per
hour. There are furthermore no regulatory obstaclesalteration from a highly disorganized lipid structure to more
Figure 3 Aggregation method in reduced intensified dispersions (upper) and pearl-like network in NLC dispersions with stabilizing
effect.
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lines for parenteral.
Drawbacks encountered in cancer chemotherapy and the
use of NLC
Numerous forms of malignancy, especially solid tumors,
have historic presented important challenges to accepted
chemotherapy. Regardless of the advancement in thera-
peutic cocktails, the conclusion of chemotherapy remains
unsatisfactory. For demonstration, the response rate of
pancreatic cancerous disease, oesophageal cancerous
disease and ovarian cancerous disease to chemotherapyFigure 4 Output of NLC Nanosuspension.are well underneath 20% [26]. Even in patients with ma-
lignancies that are more perceptive to chemotherapeutic
agencies, e.g. Breast cancerous disease, the clinical con-
clusions are generally underneath expectation [27]. In
evaluation to other pharmaceutical classes, cytotoxic
anticancer pharmaceuticals present unique difficulties
such as poor specificity, high toxicity and susceptibility
to induce pharmaceutical resistance. Conventionally
administered cytotoxic agencies often extensively and
indiscriminately join to body tissues and serum protein
in a highly unpredictable kind. Only a little part of the
drugs comes to the tumor location [28]. This may both
reduce the therapeutic efficacy and boost systemic
pharmaceutical toxicity. Furthermore, even though
cytotoxic drugs perfectly should only murder cancerous
disease units, in reality they are also toxic to non-
cancerous units, particularly to rapidly splitting up
units, e.g. skeletal part marrow units and units of the
gastrointestinal tract. The normal tissue toxicities regu-
larly occur even when benchmark therapeutic doses of
anticancer drugs are administered. The poor specificity
of cytotoxic drugs in terms of both pharmaceutical bio-
distribution as well as pharmacology at the cellular level
impersonates a significant challenge to productive antic-
ancer remedy. This poor side effect profile of cytotoxic
pharmaceuticals has considerably diminished the thera-
peutic worth of the pharmaceuticals. Counting on the
alternative of drugs, different organs or tissues can be
annoyed or impaired by the non-specific activity of the
cytotoxic agencies [29,30]. While edge effects such as
nausea, vomiting, fatigue, and hair loss are commonly
caused by almost all cytotoxic pharmaceuticals, some
side-effects are drug-specific. For demonstration,
anthracyclines can origin cardiotoxicity [31,32]. Some of
these side-effects are cumulative and life-threatening.
Cytotoxic drugs normally display a steep dose-response
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therapeutic success [33]. This leads to a tough dilemma
for clinicians to select between high drug doses with a
high risk of usual tissue toxicities or reduced pharma-
ceutical doses with reduced probabilities of therapeutic
answer. In addition, there are other obstacles to the
optimal presentation of conventional chemotherapy.
Cancerous disease units workout a kind of mechanisms
at cellular grade to weaken the toxicity of chemohera-
peutic agencies they are revealed to. These protecting
against mechanisms are sometimes categorized as
“cellular” pharmaceutical resistance. The most promin-
ent one is the multidrug resistance (MDR) phenotype,
which engages hardworking efflux of a broad variety of
cytotoxic pharmaceutical substances out of the cyto-
plasm by membrane- bound transporters [34-36]. In
supplement to cellular mechanisms, cancerous disease
units in solid tumors are inclined to be more resistant
to chemotherapy than non-aggregating cancerous dis-
ease cells due to diverse pharmaceutical permeation
obstacles, which makes it tough to achieve high intratu-
moral pharmaceutical concentration in solid tumors
[34]. This type of drug resistance, or occasionally men-
tioned as “non-cellular” drug resistance, may farther
lead to compromised clinical outcomes even though an
anticancer drug has powerful in vitro efficacy. We be-
lieve NLC offer a pledge to overcome at least some of
these obstacles.
Rationale of utilizing NLC for anticancer pharmaceutical
delivery
As the clinical outcomes of cancerous disease are usually
underneath the expectations, Nanostructured lipid car-
riers could be used as an alternative drug carrier in the
anticancer drug delivery.
In evaluation to other drug classes, a tumor is often
affiliated with a defective, leaky vascular architecture as
a result of the badly regulated environment of tumor
angiogenesis. In addition, the interstitial fluid inside a
tumor is generally insufficiently drained by a badly
formed lymphatic system. As a outcome submicron-
sized particulate issue may preferentially extravasate into
the tumor and be kept there. This is often mentioned as
the “enhanced permeability and keeping” (EPR) effect
[37]. This EPR effect can be taken benefit of by a cor-
rectly conceived nanoparticle scheme such as NLC to
achieve passive tumor targeting. By doing so, the afore-
mentioned poor tissue specificity difficulty can be par-
tially solved. Furthermore, with the improvement in
surface-engineering expertise, the bio distribution of
NLC can be further manipulated by modifying the exter-
ior physico-chemical properties of NLC to goal them to
the tissue of interest [38]. This maximizes the allowanceof pharmaceutical that can come to the aimed at tumor
sites and minimizes systemic pharmaceutical toxicity.
Like other types of drug carrier used for cytotoxic drug
consignment, such as polymeric systems and liposomes,
NLC have the benefits of personal stability, defense of la-
bile pharmaceuticals from degradation, controlled issue,
and easy preparation. At the identical time, NLC avoid
some matters came across by those pharmaceutical con-
signment systems. NLC do not carry the somewhat high
cost required for large scale production of liposomal for-
mulations. They have fewer storage and drug leakage dif-
ficulties compared to schemes such as liposomes. The
significant toxicity and acidity affiliated with a number
of biodegradable polymeric materials are also not dis-
cerned in NLC. Cytotoxic anticancer pharmaceuticals
are known for their heterogeneity. They constitute a
class of compounds with highly varied molecular struc-
ture and physicochemical properties [26]. A carrier ma-
terial, such as polymers, that can join one cytotoxic drug
may not be compatible with another one. The versatility
of NLC is thus exceedingly precious for the encapsula-
tion of cytotoxic mixtures. In addition to the natural
proficiency of NLC to effectively incorporate lipophilic
mixtures, the more lately evolved variations of NLC (e.g.
polymer-lipid hybrid nanoparticles, lipid-drug conjugate
nanoparticles, to be considered subsequent) farther elab-
orate the function of NLC for the encapsulation of
hydrophilic, ionic mixtures. numerous biocompatible
and biodegradable lipids (e.g. triglycerides such as tris-
tearin, tripalmitin, trilaurin; hard fats such as Witepsol
sequence, glyceryl behenate, cetylpalmitate, lipid acids
such as stearic acid, palmitic unpleasant) are accessible
for groundwork of NLC [39]. In supplement, NLC for-
mulations are compatible with most emulsifiers (e.g.
poloxamer 188, polysorbate 80, lecithin, sodium glyco-
cholate) accepted by pharmaceutical regulatory bureaus
[7,39]. This versatility of NLC as a pharmaceutical car-
rier makes NLC a potential generic stage for the con-
signment of diverse anticancer cytotoxic agents.
Function of NLC for cytotoxic pharmaceutical
consignment- advancement and strategies
Number of cytotoxic agencies (verapamil, cyclosporin-A and
N {4 [2 (1,2,3,4tetrahydro6,7dimethoxy-2-isoquinolinyl)-ethyl]
phenyl}9,10dihydro5methoxy 9-oxo-4-acridine carboxamide
(GG918)) which own undertakings to overcome the multi-
drug resistance phenotype in units resistant to cytotoxic
drugs have been laden into these schemes. A number of
strategies have been evolved to meet the major trials in antic-
ancer pharmaceutical consignment encompassing i) encap-
sulation of water-soluble anticancer compounds, ii) advanced
command of the rate and span of drug release and iii) avoid-
ance of systemic clearance of NLC by the reticuloendothelial
scheme (RES).
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Despite of the alternative of NLC groundwork proced-
ure, the lipid needs to be dissolve and dispersed into
lipid droplets of submicron dimensions in aqueous
medium, whether by mechanical or thermodynamic
means, to permit formation of nanoparticles. The drug
to be encapsulated desires to amply partition into the
dissolved lipid droplets to achieve good pharmaceutical
stacking [38]. It is thus conceivable that lipophilic antic-
ancer mixtures can be effectively incorporated into NLC
because they are anticipated to partition well in lipids. In
addition, some lipophilic pharmaceuticals are more rou-
tinely utilized in salt types because these salts can be
conveniently weak and administered utilizing routinely
accessible water-based vehicles (e.g. 0.9% saline) [40].
On the other hand, there are also a number of hydro-
philic, water dissolvable agents which are to be incorpo-
rated. An approach to allow significant incorporation of
these water-soluble anticancer pharmaceuticals into
NLC is apparently vital. Several schemes have been
devised to encapsulate ionic salts of cytotoxic pharma-
ceuticals. One engages the supplement of organic
contradict ions to pattern ionic in twos with the charged
drug substances described by Gasco and coworkers [41].
The group utilized decyl phosphate or hexadecyl to en-
hance loading of the saline types of doxorubicin and
idarubicin into SLN made of stearic unpleasant. Import-
ant improvements in the partitioning of the drugs into
the lipid were illustrated. For certain highly water-
soluble cytotoxic agencies, that do not bear any ascribe,
all of the aforementioned procedures, which are based
on ascribe neutralization, may not be applicable. One
likely answer is to arrange lipophilic drug derivatives
and incorporated it in NLC.
Advanced command of the rate and span of drug release
Lipid based carrier schemes evolved in early 90's often
release pharmaceuticals in a non-uniform, biphasic latest
trend. Fast issue of a large dose of drug is usually dis-
cerned primarily, pursued by slow and incomplete re-
lease of drug [42]. The quick initial pharmaceutical
issue, upon submission, is often recounted as a “burst ef-
fect” or “burst release”. It presents a potentially signifi-
cant difficulty in anticancer drug consignment because
of the powerful potency of cytotoxic compounds. A large
dose of anticancer drug quickly unpacked into the sys-
temic circulation (if administered systemically) or
released beside the localized injection site (if adminis-
tered loco- regionally) can possibly origin an important
wellbeing hazard. In NLC, crystallinity of the lipid is
decreased by mixing spatially incompatible solid lipids
or solid lipids with small amounts of oils. The profi-
ciency of NLC to have a decreased blew effect and an
increased payload of certain oil-soluble pharmaceuticalsmakes them a fairly attractive vehicle for anticancer drug
consignment. Drug issue can be slow and incomplete
from SLN after the initial burst. For instance, the release
was less than 0.1% in different schemes consigning
anticancer pharmaceuticals encompassing doxorubicin,
idarubicin and paclitaxel [41,43].
Expanded drug issue is generally considered to be an af-
firmative characteristic in most types of treatment. Al-
though, in periods of cancerous disease chemotherapy, its
influence is difficult to forecast. It has been shown that re-
lentless exposure to sub-optimal levels of cytotoxic agen-
cies may induce the sign of membrane-associated
pharmaceutical transporters (e.g. P-glycoprotein (P-gp))
[44,45] and therefore renders cancerous disease units
more drug-resistant. A NLC scheme that may release
anticancer pharmaceutical much quicker without a strong
blew release may bypass this theoretical risk.
Development of NLC schemes able to avoid clearance by
reticuloendothelial system
Following intravenous management, pharmaceutical de-
livery schemes such as polymeric nanoparticles and lipo-
somes are rapidly unblocked from the systemic
circulation by the RES, furthermore renowned as mono-
nuclear phagocyte system. RES is a part of the immune
scheme consisting of phagocytic cells, which generally
reside in the spleen, lymph nodes, and also in the liver
in the pattern of Kupffer units. These phagocytic units
can eliminate pharmaceutical carriers identified as for-
eign objects inside minutes [44,45]. RES clearance of
pharmaceutical carriers would be useful only if lymph
nodes, liver or spleen were the goal tumor site. Although
for other cancers, RES clearance is expected a foremost
barricade to systemic cytotoxic pharmaceutical consign-
ment by NLC. When a particulate pharmaceutical car-
rier is encased with hydrophilic polymers the carrier
becomes more resistant to RES clearance. This is partly
because these polymers favor exterior adsorption of pro-
teins that suppress opsonisation in vivo [46]. This type
of polymer-coated drug consignment scheme is often
mentioned to as “stealth”, for their proficiency to evi-
dently evade the surveillance of immune scheme, or
more rightly “long – circulating” drug carriers. This kind
of scheme is able to stay in the circulation for prolonged
times, with a half-life of a couple of hours in rodent
forms to as high as 55 h in human subjects [46-48].
Long-circulating NLC formulations were prepared by
coating the nanoparticles with a polymer. To facilitate
more protected attachment of the hydrophilic polymer
up on the surfaces of the lipid cores, polymer molecules
were pre-conjugated to lipophilic moieties to form
amphiphilic stealth outer layer agents. By increasing the
engrossment of the outer layer agency it was shown that
the zeta potentials of nanoparticles were decreased and
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of hydrophilic polymer substances adsorbed up on the
particle exterior using the conjugated lipophilic moieties
conspicuously shielded the exterior ascribes and increased
the hydrodynamic volumes of the nanoparticles. The use
of higher concentration of lipid and polymer furthermore
moderately expanded the polydispersity catalogue. Hence,
one should accept in mind that outer layer NLC with a
stealth agency may affect more than just the clearance
rates by the RES. Diverse physicochemical properties of
the element systems are furthermore modified, which may
considerably sway NLC presentation, security or formula-
tion stability.
Conclusion
Nano particulate pharmaceutical delivery systems offer a
large influence to overwhelm some of the obstacles to
effectively target a number of varied cell types. Despite
the recent advancement in the therapeutic, significant
challenges still present in the area of cell cancerous dis-
ease. Routinely utilized chemotherapy have given unsat-
isfactory outcomes, as the therapy is deleterious to
patient wellbeing by making patients more susceptible to
other infections and often cause death by weakening the
immune system of the persevering body. Thus, a bud-
ding interest in nanotechnology has been developed re-
markable number of advancements in latest years with a
main aim on current cancer therapy.
Nanoparticulate delivery of anticancer pharmaceuticals
to tumor tissues can be accomplished by organizing the
nanodrug carrier. Nanotechnology is anticipated to play
a progressively important function in the diagnostics,
prognostics and administration of aimed at cancerous
disease treatments. Nanotechnology is very quick
expanding area of study foreseen to lead to development
of innovative, sophisticated applications which recognize
skin cancer units, consign drugs to target tissue, describ-
ing conclusion of treatment, and supervise intracellular
changes to help avert precancerous cells from evolving
malignant. The future remains exciting and wide open
for on-going efforts by scientists, investigators and med-
ical staff can genuinely ensure to do big things using the
very little. The perfect consignment scheme would be
targeted and accurately controlled. To goal nanoparticles
to the desired tissues, a number of procedures have been
evolved. These include physical means such as control-
ling the dimensions, ascribe and hydrophobicity of the
particles. In supplement, targeting substances, such as
antibodies and peptides, that identify exact cell exterior
proteins and receptors, can be conjugated to the nano-
particle exterior to expressly goal specific cell types.
Competing interests
The authors declare that they have no competing interests.Authors’ contributions
SS was responsible for the layout and initial idea for the manuscript and
participated in researching the literature and critical discussion of the work.
RV wrote the manuscript. Both the authors read and approved the final
manuscript.Acknowledgements
The authors wish to thank Department of Pharmacy, Annamalai University
for supporting this work.
Received: 14 August 2012 Accepted: 26 October 2012
Published: 20 November 2012References
1. Barratt GM: Therapeutic applications of colloidal drug carriers. Pharm Sci
Technolo Today 2000, 3:163–171.
2. Mehnert W, Mader K: Solid lipid nanoparticles: production,
characterization and applications. Adv Drug Deliv Rev 2001, 47:165–196.
3. Mainardes RM, Silva LP: Drug delivery systems: past, present, and future.
Curr Drug Targets 2004, 5:449–455.
4. Gregoriadis G, Florence AT, Patel HM: Liposomes in drug delivery. In Drug
Targeting and Delivery. Edited by Florence AT, Chur GG. Harwood Academic
Publishers GmbH; 1993.
5. Choi MJ, Maibach HI: Liposomes and niosomes as topical drug delivery
systems. Skin Pharmacol Physiol 2005, 18:209–219.
6. Selvamuthukumar S, Anandam S, kannan K, Manavalan R: Nanosponges: A
novel class of drug delivery system - Review. J Pharm Pharmaceut Sci
2012, 15:103–111.
7. Smith A, Hunneyball lM: Evaluation of poly (lactic acid) as a
biodegradable drug delivery system for parenteral administration. Int J
Pharm 1986, 30:215–220.
8. Lherm C, Müller RH, Puisieux F, Couvreur P: Alkylcyanoacrylate Drug
Carriers II: Cytotoxicity of Cyanoacrylate Nanoparticles with Different
Alkyl Chain Length. Int J Pharm 1992, 84:13–22.
9. Lucks JS, Müller RH: Medication vehicles made of solid lipid particles (solid
lipid nanospheres SLN), in EP0000605497. Germany: 1996.
10. Muller RH, Radtke M, Wissing SA: Solid lipid nanoparticles (SLN) and
nanostructured lipid carriers (NLC) in cosmetic and dermatological
preparations. Adv Drug Deliv Rev 2002, 54:131–155.
11. Saupe A, Wissing SA, Lenk A, Schmidt C, Müller RH: Solid Lipid
Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) – Structural
investigations on two different carrier systems. Bio-Med Mater Eng 2005,
15:393–402.
12. Muller RH, Radtke M, Wissing SA: Nanostructured lipid matrices for
improved microencapsulation of drugs. Inte J Pharm 2002, 242:121–128.
13. Jenning V, Thunemann AF, Gohla SH: Characterisation of a novel solid
lipid nanoparticle carrier system based on binary mixtures of liquid and
solid lipids. Int J Pharm 2000, 199:167–177.
14. Jenning V, Mader K, Gohla S: Solid lipid nanoparticles (SLN) based on
binary mixtures of liquid and solid lipids: a 1H-NMR study. Int J Pharm
2000, 205:15–21.
15. Muller RH, Mader K, Gohla S: Solid lipid nanoparticles (SLN) for controlled
drug delivery- a review of the state of the art. Eur J Pharm Biopharm 2000,
50:161–177.
16. Muller RH, Gohla S, Dingler A, Schneppe T: Large scale production of solid
lipid nanoparticles (SLNTM) and nanosuspensions (DissoCubesTM). In
Handbook of Pharmaceutical Controlled Release Technology. Edited by Wise
DL. 2000:359–376.
17. Uner M: Preparation, characterization and physico-chemical properties of
solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC):
their benefits as colloidal drug carrier systems. Die Pharmazie 2006,
61:375–386.
18. Bunjes H, Westesen K, Koch MH: Crystallization tendency and polymorphic
transition in triglyceride nanoparticles. Int J Pharm 1996, 129:159–173.
19. Muller RH: Extended patent on the basis of (6), PCT application PCT/EP00/
04112. 2000.
20. Muller RH, et al: PCT application PCT/EP00/04111. 2000.
21. Radtke M, Müller RH: Stability study of creams containing cyclosporine
SLN™. Int Symp Control Rel Bioact Mater 2001, 28:472–473.
Selvamuthukumar and Velmurugan Lipids in Health and Disease 2012, 11:159 Page 8 of 8
http://www.lipidworld.com/content/11/1/15922. Radtke M, Müller RH: Novel concept of topical cyclosporine delivery with
supersaturated SLN™ creams. Int Symp Control Rel Bioact Mater 2001,
28:470–471.
23. Freitas C, Müller RH: Correlation between long-term stability of solid lipid
nanoparticles (SLN) and crystallinity of the lipid phase. Eur J Pharm
Biopharm 1999, 47:125–132.
24. Lippacher A: Pharmaceutical Characterization of Liquid and Semi-Soid
SLN Dispersions for Topical Application. In PhD Thesis. Germany: Free
University of Berlin; 2001.
25. Velmurugan R, Selvamuthukumar S, Manavalan R: Multi criteria decision
making to select the suitable method for the preparation of
nanoparticles using an analytical hierarchy process. Die Pharmazie 2011,
66:836–842.
26. Ewesuedo RB, Ratain MJ: Principles of cancer chemotherapy. In
Oncologic Therapeutics. Edited by Vokes EE, Golomb HM. New York:
Springer; 2003:19–66.
27. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for
early breast cancer: an overview of the randomized trials. Lancet 1998,
352:930–942.
28. Ratain MJ, Mick R: Principles of pharmacokinetics and
pharmacodynamics. In Principles of Antineoplastic Drug Development and
Pharmacology. Edited by Schilsky RL, Milano GA, Ratain MJ. New York:
Marcel Dekker; 1996:123–142.
29. Tipton JM: Side effects of cancer chemotherapy. In Handbook of Cancer
Chemotherapy. Edited by Skeel RT. Philedelphia: Lippincott Williams &
Wilkins; 2003:561–580.
30. Powis G: A unique opportunity to study human toxicology. In The Toxicity
of Anticancer Drugs. Edited by Powis G, Hacker MP. Toronto: Pergamon
Press; 1991:1–9.
31. Lu P: Monitoring cardiac function in patients receiving doxorubicin. Nucl
Med 2005, 35:197–201.
32. Kalyanaraman B, Joseph J, Kalivendi S, Wang S, Konorev E, Kotamraju S:
Doxorubicin-induced apoptosis: implications in cardiotoxicity. Mol Cell
Biochem 2002, 234:119–124.
33. Hryniuk WA, Figueredo A, Goodyear M: Applications of dose intensity to
problems in chemotherapy of breast and colorectal cancer. Oncol 1987,
11:3–11.
34. Gieseler F, Rudolph P, Kloeppel G, Foelsch UR: Resistance mechanisms of
gastrointestinal cancers: why does conventional chemo- therapy fail? Int
J Colorectal Dis 2003, 18:470–480.
35. Baird RD, Kaye SB: Drug resistance reversal - are we getting closer? Eur J
Cancer 2003, 39:2450–2461.
36. Safa AR: Multidrug resistance. In Principles of Antineoplastic Drug
Development and Pharmacology. Edited by Schilsky RL, Milano GA, Ratain
MJ. New York: Marcel Dekker; 1996:457–486.
37. Matsumura Y, Maeda H: A new concept for macromolecular therapeutics
in cancer chemotherapy: mechanism of tumoritropic accumulation of
proteins and the antitumor agent. Cancer Res 1968, 6:193–210.
38. Mehnert W, Mader K: Solid lipid nanoparticles: production,
characterization and applications. Adv Drug Deliv Rev 2001, 47:165–196.
39. Muller RH, Mader K, Gohla S: Solid lipid nanoparticles (SLN) for controlled
drug delivery— a review of the state of the art. Eur J Pharm Biopharm
2000, 50:61–177.
40. Pratt WB, Ruddon RW, Ensminger WD, Maybaum J: The Anticancer Drugs.
New York: Oxford University Press; 1994.
41. Cavalli R, Caputo O, Gasco MR: Solid lipospheres of doxorubicin and
idarubicin. Int J Pharm 1993, 89:9–12.
42. Zur Muhlen A, Schwarz C, Mehnert W: Solid lipid nanoparticles (SLN) for
controlled drug delivery— drug release and release mechanism. Eur J
Pharm Biopharm 1998, 45:149–155.
43. Cavalli R, Caputo O, Gasco MR: Preparation and characterization of solid
lipid nanospheres containing paclitaxel. Eur J Pharm Sci 2000, 10:305–309.
44. Hahn SM, Russo A, Cook JA, Mitchell JB: A multidrug-resistant breast
cancer line induced by weekly exposure to doxorubicin. Int J Oncol 1999,
14:273–279.
45. Campone M, Vavasseur F, Le MT, Cabellec K, Meflah FM, Vallette L:
Induction of chemoresistance in HL-60 cells concomitantly causes a
resistance to apoptosis and the synthesis of P-glycoprotein. Leukemia
2001, 15:1377–1387.46. Moghimi SM, Szebeni J: Stealth liposomes and long circulating
nanoparticles: critical issues in pharmacokinetics, opsonization and
protein-binding properties. Prog Lipid Res 2003, 42:463–478.
47. Gabizon AA, Muggia FM: In Long Circulating Liposomes: Old Drugs, New
Therapeutics. Edited by Woodle MC, Storm G. Austin, Texas: Springer-Verlag
and Landes Bioscience; 1998:165–174.
48. Park JW: Liposome-based drug delivery in breast cancer treatment. Breast
Cancer Res 2002, 4:95–99.
49. Zara GP, Cavalli R, Bargoni A, Fundaro A, Vighetto D, Gasco MR: Intravenous
administration to rabbits of non-stealth and stealth doxorubicin-loaded
solid lipid nanoparticles at increasing concentrations of stealth agent:
pharmacokinetics and distribution of doxorubicin in brain and other
tissues. J Drug Target 2002, 10:327–335.
doi:10.1186/1476-511X-11-159
Cite this article as: Selvamuthukumar and Velmurugan: Nanostructured
Lipid Carriers: A potential drug carrier for cancer chemotherapy. Lipids in
Health and Disease 2012 11:159.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
